Bionxt has completed manufacturing of a batch of BNT23001, its under-the-tongue formulation of cladribine, for use in MS ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
AI-driven robotics platform reduces drug formulation development time from years to months SACRAMENTO, Calif., May 19, 2025 /PRNewswire/ -- Persist AI, a pioneer in AI-driven robotics for ...
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new ...
“Developed to meet the real-world needs of patients, the new BRUKINSA tablet formulation aims to simplify treatment, reduce pill burden, and enhance ease of administration, reflecting our continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results